Summary:
Evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo for the
treatment of agitation in patients with dementia of the Alzheimer’s type
Someone you care for with Alzheimer's dementia exhibiting excessive motor activity, verbal and/or physical aggression? If so, they may qualify for the ASPECTTM clinical research study. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug for agitation associated with Alzheimer's dementia. To be eligible for this study, a potential participant must:
- Be between the ages of 50 and 90
- Have a diagnosis of probable Alzheimer’s dementia
- Have moderate-to-severe agitation that interferes with their daily life
- Have a reliable caregiver who spends a minimum of 2 hoursper day, 4 days per week with them and is willing and able to comply with all study procedures
Qualified Participants May Receive:
$2000 per 10 office visits.